Skip to main content
OpenTrials
Completed

NCT Number: NCT02541123

Evaluation of Biomarker Kinetics After Mild Brain Injury Trauma

The primary objective of the clinical trial is to evaluate the effect of time on levels of Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) biomarker levels in a population of head injured subjects over the age of 18 presenting acutely with a Glasgow Coma Scale score 13-15 as well as in a group of uninjured control subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Klinikum rechts der Isar of the Technical University of Munich, Munich, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Head Injured Cohorts Inclusion Criteria:

  • At least 18 years of age at screening.
  • Presented with a suspected traumatically induced head injury, as a result of insult to the head from an external force.
  • Workup includes head CT scan, as part of clinical emergency care and CT result (CT-positive or CT-negative for acute intracranial lesions) based on the local neuroradiologist's review is available to study staff.
  • CT scan and CT report used to determine eligibility must be available.
  • Glasgow Coma Scale score of 13-15 at the time of Informed Consent.
  • Weighs at least 110lbs (50kg), has not donated blood within the last 8 weeks, and is not anemic or has any other blood disorder which requires routine transfusions.
  • First study blood sample is able to be collected into a cohort that has not been closed to enrollment
  • Able to participate for up to 11 days following head injury.
  • Subject or legal representative is willing to undergo the Informed Consent process prior to enrollment into this study.
  • FOR CT NEGATIVE COHORTS ONLY: Subject must have experienced a Loss of Consciousness (LOC) < 30 minutes, any Alteration of Consciousness (AOC), or any Post-traumatic amnesia (PTA) following the suspected head injury AND be expected to be admitted to the hospital, or remain in hospital for at least 24 hours in order to complete Visit 1 blood draws

Head Injured Cohorts Exclusion Criteria:

  • Participating in an interventional, therapeutic clinical study that may affect the results of this study (an observational study would be acceptable).
  • Time of injury cannot be determined.
  • Primary diagnosis of ischemic or hemorrhagic stroke.
  • Venipuncture not feasible
  • Neurodegenerative disease or other neurological disorder including dementia, Parkinson's disease, multiple sclerosis, seizure disorder, or brain tumors.
  • History of neurosurgery within the last 30 days.
  • Administration of blood transfusion after head injury and prior to the study blood draw.
  • Female who is pregnant or lactating.
  • Subject is otherwise determined by the Investigator to be an unsuitable candidate for participation.

Control Cohort Inclusion Criteria

  • At least 18 years of age at screening
  • Weighs at least 110lbs (50kg), has not donated blood within the last 8 weeks, and is not anemic or has any other blood disorder which requires routine transfusions.
  • Healthy with no chronic or acute medical, neurologic, or psychiatric conditions (to the best of their knowledge).
  • Able to participate for up to 5 hours following the first study blood draw.
  • Willing to undergo the Informed Consent process prior to enrollment into this study.
  • Subject is able to be enrolled into a control cohort that has not yet been closed to enrollment

Control Cohort Exclusion Criteria

  • Participating in an interventional, therapeutic clinical study that may affect results of this study (an observational study would be acceptable).
  • Subject has sustained any significant bodily injury within the past week.
  • Venipuncture not feasible (i.e., skin integrity compromised at the venipuncture sites, blood vessel calcification (i.e., IV drug users, advanced atherosclerosis) both upper limbs missing (congenital or amputee)).
  • Neurodegenerative disease or other neurological disorder including dementia, Parkinson's disease, multiple sclerosis, seizure disorder, or brain tumors.
  • Female who is pregnant or lactating
  • History of neurosurgery within the last 30 days.
  • Subject is otherwise determined by the Investigator to be an unsuitable candidate for participation

Treatment and study plan

Blood Draw

Other

Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7. Control group only undergoes 2 blood draws 4 hours apart on Day 1.

Primary outcomes

  1. Change in correlation of Banyan UCH-L1/GFAP Detection Assay result with acute intracranial lesions on head CT scan

    Time frame: initial, 4hr, 8hr,12hr,16hr, 20hr, 24hr, Day 7

Sponsors and collaborators

Lead sponsor

Banyan Biomarkers, Inc

Industry

Collaborators

  • United States Department of Defense

Registry information

Official study title

A Prospective Evaluation of Uch-l1 and Gfap Biomarker Kinetics After Mild Brain Injury Trauma

Acronym: VIGILANT

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Sep 4, 2015
Registry last updated
Dec 16, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.